Cartesian Therapeutics, Inc. Payments of Stock Issuance Costs
Cartesian Therapeutics, Inc. (RNAC) reported Payments of Stock Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-06
- Cartesian Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Cartesian Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Cartesian Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $102.00K, a 54.55% increase year-over-year.
- Cartesian Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $43.00K.
- Cartesian Therapeutics, Inc. payments of stock issuance costs for fiscal 2025 was $624.00K, a 845.45% increase from fiscal 2024.
- Cartesian Therapeutics, Inc. payments of stock issuance costs for fiscal 2024 was $66.00K.
- Cartesian Therapeutics, Inc. payments of stock issuance costs for fiscal 2023 was $0.00.
- Cartesian Therapeutics, Inc. payments of stock issuance costs for fiscal 2018 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 3 month as first filed | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $102.00K derived: sum of 3 quarters · filed 2026-08-06 | $145.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $102.00K derived: sum of 2 quarters · filed 2026-04-30 | $145.00K derived: sum of 3 quarters · filed 2026-04-30 | $170.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $145.00K derived: sum of 2 quarters · filed 2026-03-09 | $170.00K derived: sum of 3 quarters · filed 2026-08-06 | $624.00K 10-K · filed 2026-03-09 | |
| 2025-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $68.00K derived: sum of 2 quarters · filed 2026-08-06 | $522.00K 10-Q · filed 2025-11-06 | $588.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $479.00K 10-Q · filed 2026-08-06 | $545.00K derived: sum of 3 quarters · filed 2026-08-06 | $545.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $454.00K 10-Q · filed 2026-04-30 | $520.00K derived: sum of 2 quarters · filed 2026-04-30 | $520.00K derived: sum of 3 quarters · filed 2026-04-30 | $520.00K derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $66.00K derived: sum of 2 quarters · filed 2026-03-09 | $66.00K derived: sum of 3 quarters · filed 2026-03-09 | $66.00K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 | ||||
| 2019-09-30 | $37.00K 10-Q · filed 2019-11-08 | ||||
| 2019-03-31 | $344.00K 10-Q · filed 2019-11-08 | $344.10K 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-03-15 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $0.00 derived: sum of 2 quarters · filed 2019-03-15 | $0.00 derived: sum of 3 quarters · filed 2019-03-15 | $0.00 10-K · filed 2019-03-15 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | $35.00K derived: sum of 4 quarters · filed 2019-03-15 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $0.00 10-Q · filed 2017-08-11 | $35.00K derived: sum of 3 quarters · filed 2019-03-15 | $1.45M derived: sum of 4 quarters · filed 2019-03-15 | |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-11 | $35.00K derived: sum of 2 quarters · filed 2019-03-15 | $1.45M derived: sum of 3 quarters · filed 2019-03-15 | $2.42M derived: sum of 4 quarters · filed 2019-03-15 | |
| 2016-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $1.45M derived: sum of 2 quarters · filed 2019-03-15 | $2.42M derived: sum of 3 quarters · filed 2019-03-15 | $4.10M 10-K · filed 2019-03-15 | |
| 2016-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $2.38M derived: sum of 2 quarters · filed 2017-11-07 | $4.07M 10-Q · filed 2017-11-07 | $4.37M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-06-30 | $966.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $2.65M 10-Q · filed 2017-08-11 | $2.95M derived: sum of 3 quarters · filed 2018-03-15 | ||
| 2016-03-31 | $1.68M 10-Q · filed 2017-05-11 | $1.99M derived: sum of 2 quarters · filed 2018-03-15 | |||
| 2015-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $302.00K 10-K · filed 2018-03-15 | |||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-10 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |